Switch to:
Also traded in: Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.37
GILD's Cash to Debt is ranked lower than
91% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. GILD: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
GILD' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.39 Max: 4122.75
Current: 0.37
0.15
4122.75
Equity to Asset 0.28
GILD's Equity to Asset is ranked lower than
85% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. GILD: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.59 Max: 0.95
Current: 0.28
0.21
0.95
Interest Coverage 28.07
GILD's Interest Coverage is ranked lower than
71% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 28.07 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 37.05 Max: 2513.81
Current: 28.07
11.11
2513.81
F-Score: 5
Z-Score: 4.77
M-Score: -2.35
WACC vs ROIC
11.61%
76.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 65.39
GILD's Operating margin (%) is ranked higher than
98% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. GILD: 65.39 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s Operating margin (%) Range Over the Past 10 Years
Min: -25.07  Med: 50.02 Max: 61.33
Current: 65.39
-25.07
61.33
Net-margin (%) 52.81
GILD's Net-margin (%) is ranked higher than
96% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. GILD: 52.81 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s Net-margin (%) Range Over the Past 10 Years
Min: -39.32  Med: 37.05 Max: 48.62
Current: 52.81
-39.32
48.62
ROE (%) 104.70
GILD's ROE (%) is ranked higher than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. GILD: 104.70 )
Ranked among companies with meaningful ROE (%) only.
GILD' s ROE (%) Range Over the Past 10 Years
Min: -49.14  Med: 45.97 Max: 90.32
Current: 104.7
-49.14
90.32
ROA (%) 38.07
GILD's ROA (%) is ranked higher than
98% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. GILD: 38.07 )
Ranked among companies with meaningful ROA (%) only.
GILD' s ROA (%) Range Over the Past 10 Years
Min: -30.31  Med: 27.37 Max: 42.28
Current: 38.07
-30.31
42.28
ROC (Joel Greenblatt) (%) 623.08
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. GILD: 623.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -71.55  Med: 176.02 Max: 484.47
Current: 623.08
-71.55
484.47
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
89% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. GILD: 41.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 13.2  Med: 43.40 Max: 70.4
Current: 41.7
13.2
70.4
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. GILD: 55.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.3  Med: 33.00 Max: 116.7
Current: 55.6
-16.3
116.7
EPS Growth (3Y)(%) 60.60
GILD's EPS Growth (3Y)(%) is ranked higher than
94% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. GILD: 60.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 26.90 Max: 143.3
Current: 60.6
0
143.3
» GILD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GILD Guru Trades in Q2 2015

Westport Asset Management 95,000 sh (New)
John Hussman 75,000 sh (New)
Ray Dalio 81,721 sh (+224.02%)
Julian Robertson 399,411 sh (+72.52%)
David Dreman 9,525 sh (+70.70%)
Paul Tudor Jones 10,380 sh (+58.84%)
NWQ Managers 145,200 sh (+28.38%)
John Buckingham 57,343 sh (+26.64%)
John Rogers 1,106,494 sh (+24.10%)
Pioneer Investments 3,274,401 sh (+7.47%)
Murray Stahl 8,950 sh (+2.87%)
Ken Fisher 791,630 sh (+0.26%)
First Eagle Investment 400 sh (unchged)
Dodge & Cox 4,250 sh (unchged)
Steven Cohen Sold Out
Ronald Muhlenkamp 218,620 sh (-0.05%)
Joel Greenblatt 1,068,128 sh (-3.58%)
Mario Gabelli 43,925 sh (-11.21%)
Lee Ainslie 2,340 sh (-11.70%)
RS Investment Management 125,840 sh (-13.11%)
Jeremy Grantham 3,600 sh (-21.74%)
Louis Moore Bacon 19,142 sh (-56.88%)
Jim Simons 1,310,100 sh (-67.51%)
John Burbank 2,295 sh (-94.97%)
» More
Q3 2015

GILD Guru Trades in Q3 2015

John Keeley 29,029 sh (New)
John Burbank 29,586 sh (+1189.15%)
Ray Dalio 222,121 sh (+171.80%)
RS Investment Management 156,503 sh (+24.37%)
John Rogers 1,313,500 sh (+18.71%)
David Dreman 11,228 sh (+17.88%)
NWQ Managers 169,500 sh (+16.74%)
Murray Stahl 9,950 sh (+11.17%)
John Buckingham 61,912 sh (+7.97%)
Pioneer Investments 3,283,529 sh (+0.28%)
Lee Ainslie 2,340 sh (unchged)
David Carlson 550,000 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Dodge & Cox 4,250 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
John Hussman 75,000 sh (unchged)
First Eagle Investment 400 sh (unchged)
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 217,990 sh (-0.29%)
Mario Gabelli 43,750 sh (-0.40%)
Julian Robertson 352,311 sh (-11.79%)
Joel Greenblatt 936,982 sh (-12.28%)
Ken Fisher 562,391 sh (-28.96%)
Paul Tudor Jones 7,300 sh (-29.67%)
Jim Simons 280,300 sh (-78.60%)
» More
Q4 2015

GILD Guru Trades in Q4 2015

Diamond Hill Capital 2,070 sh (New)
T Rowe Price Equity Income Fund 1,250,000 sh (New)
Jeff Auxier 2,282 sh (New)
Jerome Dodson 200,000 sh (New)
Louis Moore Bacon 20,493 sh (New)
Jim Simons 2,319,448 sh (+727.49%)
Paul Tudor Jones 16,614 sh (+127.59%)
Julian Robertson 394,411 sh (+11.95%)
Pioneer Investments 3,392,997 sh (+3.33%)
John Buckingham 63,796 sh (+3.04%)
Murray Stahl 10,000 sh (+0.50%)
Ken Fisher 563,917 sh (+0.27%)
First Eagle Investment 400 sh (unchged)
David Carlson 550,000 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Lee Ainslie 2,340 sh (unchged)
John Rogers 1,313,500 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
John Hussman Sold Out
John Burbank Sold Out
David Dreman Sold Out
John Keeley Sold Out
Ronald Muhlenkamp 217,975 sh (-0.01%)
RS Investment Management 155,231 sh (-0.81%)
NWQ Managers 166,900 sh (-1.53%)
Ray Dalio 218,121 sh (-1.80%)
Mario Gabelli 42,700 sh (-2.40%)
Joel Greenblatt 874,246 sh (-6.70%)
Dodge & Cox 3,750 sh (-11.76%)
» More
Q1 2016

GILD Guru Trades in Q1 2016

Steven Cohen 700 sh (New)
George Soros 3,600 sh (New)
David Dreman 23,210 sh (New)
Leon Cooperman 516,989 sh (New)
Jeremy Grantham 97,600 sh (+2611.11%)
First Eagle Investment 9,200 sh (+2200.00%)
Paul Tudor Jones 41,349 sh (+148.88%)
Lee Ainslie 5,630 sh (+140.60%)
Dodge & Cox 7,620 sh (+103.20%)
Jerome Dodson 310,000 sh (+55.00%)
Jeff Auxier 2,982 sh (+30.67%)
Ray Dalio 249,821 sh (+14.53%)
Joel Greenblatt 967,642 sh (+10.68%)
Pioneer Investments 3,700,967 sh (+9.08%)
T Rowe Price Equity Income Fund 1,353,600 sh (+8.29%)
David Carlson 570,000 sh (+3.64%)
John Rogers 1,360,492 sh (+3.58%)
Ronald Muhlenkamp 217,990 sh (+0.01%)
Murray Stahl 10,000 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
Louis Moore Bacon Sold Out
Diamond Hill Capital Sold Out
John Buckingham 63,487 sh (-0.48%)
RS Investment Management 151,102 sh (-2.66%)
Mario Gabelli 40,690 sh (-4.71%)
Ken Fisher 487,030 sh (-13.63%)
NWQ Managers 116,000 sh (-30.50%)
Jim Simons 723,948 sh (-68.79%)
Julian Robertson 38,511 sh (-90.24%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors

Ratios

vs
industry
vs
history
P/E(ttm) 7.34
GILD's P/E(ttm) is ranked higher than
89% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. GILD: 7.34 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s P/E(ttm) Range Over the Past 10 Years
Min: 6.96  Med: 19.70 Max: 45.41
Current: 7.34
6.96
45.41
Forward P/E 6.82
GILD's Forward P/E is ranked higher than
87% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. GILD: 6.82 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 7.34
GILD's PE(NRI) is ranked higher than
88% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. GILD: 7.34 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s PE(NRI) Range Over the Past 10 Years
Min: 6.96  Med: 19.72 Max: 45.49
Current: 7.34
6.96
45.49
Price/Owner Earnings (ttm) 6.84
GILD's Price/Owner Earnings (ttm) is ranked higher than
89% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. GILD: 6.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GILD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.31  Med: 17.96 Max: 74.51
Current: 6.84
6.31
74.51
P/B 8.76
GILD's P/B is ranked lower than
82% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. GILD: 8.76 )
Ranked among companies with meaningful P/B only.
GILD' s P/B Range Over the Past 10 Years
Min: 4.15  Med: 8.44 Max: 18.71
Current: 8.76
4.15
18.71
P/S 3.90
GILD's P/S is ranked higher than
78% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. GILD: 3.90 )
Ranked among companies with meaningful P/S only.
GILD' s P/S Range Over the Past 10 Years
Min: 3.53  Med: 7.71 Max: 14.38
Current: 3.9
3.53
14.38
PFCF 7.25
GILD's PFCF is ranked higher than
89% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. GILD: 7.25 )
Ranked among companies with meaningful PFCF only.
GILD' s PFCF Range Over the Past 10 Years
Min: 6.51  Med: 21.40 Max: 57.83
Current: 7.25
6.51
57.83
POCF 6.94
GILD's POCF is ranked higher than
86% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. GILD: 6.94 )
Ranked among companies with meaningful POCF only.
GILD' s POCF Range Over the Past 10 Years
Min: 6.27  Med: 19.28 Max: 51.28
Current: 6.94
6.27
51.28
EV-to-EBIT 5.97
GILD's EV-to-EBIT is ranked higher than
78% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. GILD: 5.97 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 14.05 Max: 209.2
Current: 5.97
-154.2
209.2
EV-to-EBITDA 5.68
GILD's EV-to-EBITDA is ranked higher than
79% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. GILD: 5.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 13.20 Max: 168
Current: 5.68
-189.9
168
PEG 0.27
GILD's PEG is ranked higher than
95% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. GILD: 0.27 )
Ranked among companies with meaningful PEG only.
GILD' s PEG Range Over the Past 10 Years
Min: 0.13  Med: 0.66 Max: 3.75
Current: 0.27
0.13
3.75
Shiller P/E 26.86
GILD's Shiller P/E is ranked higher than
79% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. GILD: 26.86 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s Shiller P/E Range Over the Past 10 Years
Min: 25.83  Med: 58.89 Max: 2078
Current: 26.86
25.83
2078
Current Ratio 1.77
GILD's Current Ratio is ranked lower than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. GILD: 1.77 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 6.53 Max: 20.22
Current: 1.77
1.09
20.22
Quick Ratio 1.59
GILD's Quick Ratio is ranked lower than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. GILD: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.08 Max: 20.22
Current: 1.59
0.83
20.22
Days Inventory 165.21
GILD's Days Inventory is ranked lower than
63% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. GILD: 165.21 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 228.97 Max: 328.95
Current: 165.21
148.53
328.95
Days Sales Outstanding 68.50
GILD's Days Sales Outstanding is ranked lower than
55% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. GILD: 68.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.89  Med: 71.19 Max: 84.93
Current: 68.5
65.89
84.93
Days Payable 79.90
GILD's Days Payable is ranked higher than
61% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. GILD: 79.90 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 92.02  Med: 172.90 Max: 309.16
Current: 79.9
92.02
309.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
GILD's Dividend Yield is ranked higher than
73% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. GILD: 2.00 )
Ranked among companies with meaningful Dividend Yield only.
GILD' s Dividend Yield Range Over the Past 10 Years
Min: 0.36  Med: 1.06 Max: 2.08
Current: 2
0.36
2.08
Dividend Payout 0.15
GILD's Dividend Payout is ranked higher than
79% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. GILD: 0.15 )
Ranked among companies with meaningful Dividend Payout only.
GILD' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.14 Max: 0.17
Current: 0.15
0.14
0.17
Forward Dividend Yield 2.19
GILD's Forward Dividend Yield is ranked higher than
73% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. GILD: 2.19 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.02
GILD's Yield on cost (5-Year) is ranked higher than
62% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. GILD: 2.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GILD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.36  Med: 0.88 Max: 2.08
Current: 2.02
0.36
2.08
3-Year Average Share Buyback Ratio 0.20
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GILD: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.3  Med: -1.85 Max: 6.1
Current: 0.2
-16.3
6.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 50.93
GILD's Price/Tangible Book is ranked lower than
97% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. GILD: 50.93 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.09  Med: 10.17 Max: 214.73
Current: 50.93
2.09
214.73
Price/Projected FCF 0.95
GILD's Price/Projected FCF is ranked higher than
92% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. GILD: 0.95 )
Ranked among companies with meaningful Price/Projected FCF only.
GILD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 2.14 Max: 20.25
Current: 0.95
0.8
20.25
Price/Median PS Value 0.50
GILD's Price/Median PS Value is ranked higher than
80% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. GILD: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.41 Max: 5.5
Current: 0.5
0.5
5.5
Price/Peter Lynch Fair Value 0.29
GILD's Price/Peter Lynch Fair Value is ranked higher than
93% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. GILD: 0.29 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.31  Med: 0.97 Max: 9.13
Current: 0.29
0.31
9.13
Price/Graham Number 4.07
GILD's Price/Graham Number is ranked lower than
63% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. GILD: 4.07 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.64  Med: 3.62 Max: 15.81
Current: 4.07
1.64
15.81
Earnings Yield (Greenblatt) (%) 16.80
GILD's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. GILD: 16.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GILD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 6.80 Max: 16.6
Current: 16.8
0.5
16.6
Forward Rate of Return (Yacktman) (%) 60.62
GILD's Forward Rate of Return (Yacktman) (%) is ranked higher than
97% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 14.18 vs. GILD: 60.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GILD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.7  Med: 5.80 Max: 60.9
Current: 60.62
0.7
60.9

More Statistics

Revenue (TTM) (Mil) $32,839
EPS (TTM) $ 11.69
Beta1.39
Short Percentage of Float1.73%
52-Week Range $81.28 - 123.37
Shares Outstanding (Mil)1,331.82

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 30,760 30,504 29,758
EPS ($) 12.16 12.58 13.25
EPS without NRI ($) 12.16 12.58 13.25
EPS Growth Rate
(3Y to 5Y Estimate)
-0.18%
» More Articles for NAS:GILD

Headlines

Articles On GuruFocus.com
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity May 22 2016 
Gilead Sciences Appears to Have Bottomed: Time to Buy? May 20 2016 
Is Seasonal Investing the Best Way to Approach the Market? May 13 2016 
John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
The PBM Empire Strikes Back May 10 2016 
There Are Many Reasons to be Optimistic About Gilead's Prospects May 03 2016 
Gilead, Fossil Among Stocks Trading Below Lynch Earnings Line Apr 13 2016 
Take 5: Consider Stocking Up on Gilead Sciences Apr 12 2016 
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Apr 10 2016 

More From Other Websites
Gilead Subpoenaed as Feds Probe Charity Connections May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... May 27 2016
Expected amount of compensation and settlement in the planned domination and profit transfer... May 27 2016
3 Stand-Out Health Care Stocks for Dividends and Growth May 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences... May 27 2016
Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C... May 27 2016
Gilead Sciences: Why HIV Sales Could Save the Day May 27 2016
EU regulators back approval of Gilead's new hep C drug May 27 2016
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the... May 27 2016
EU regulators recommend approving Gilead's new hepatitis C drug May 27 2016
7:26 am Gilead Sciences confirms positive CHMP opinion for co's marketing authorization application... May 27 2016
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the... May 27 2016
Gilead Subpoenaed as Feds Probe Drugmaker-Charity Connections May 27 2016
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016
Investors Eager for Gilead to Make Big Moves May 26 2016
Biotech Giant Gilead Sciences Goes on Sale May 26 2016
Please Gilead, Celgene and Amgen. Don't Buy Medivation. May 26 2016
7 Companies in the Fight to Defeat the Zika Virus May 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)